News | January 20, 2026
Avalon clinches majority investment to expand future of diagnostic intelligence
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Heart failure affects an estimated 64.3 million people worldwide
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Subscribe To Our Newsletter & Stay Updated
